Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine Triacetate SCHEMBL7924235 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL16455208 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL19308912 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL12928917 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL19308849 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL12900042 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL14950624 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL10350038 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL15279673 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL8904824 | 0.99 | LMNA (0.63) | LMNATHRBSMN1; SMN2HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284341-B1 | URIDINE TRIACETATE AMORPHOUS FORMULATION | PHARMA CINQ LLC (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-12528046-B2 | High performance CO2 capture solvent compositions, and CO2 capture systems and processes utilizing same | SUSTEON INC. (US) | 2026-01-20 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4561539-A1 | URIDINE TRIACETATE AMORPHOUS FORMULATION AND USES THEREOF | Pharma Cinq, LLC (US) | 2025-06-04 | — | — | EP | claimed |
| CN-119816299-A | Amorphous formulations of uridine triacetate and uses thereof | 制药五有限责任公司 | 2025-04-11 | — | — | CN | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-3672615-B1 | FBSA-BASED THERAPEUTIC AND RADIOIMAGING CONJUGATES TARGETING CARBONIC ANHYDRASE POSITIVE CANCERS | PURDUE RESEARCH FOUNDATION (US) | 2025-04-02 | — | — | EP | claimed |
| US-20010005719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | WELLSTAT THERAPEUTICS CORPORATION | 2001-06-28 | — | — | US | claimed |
| EP-1109453-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | Wellstat Therapeutics Corporation (US) | 2001-06-27 | — | — | EP | claimed |
| WO-2000050043-A1 | METHODS OF TREATMENT OF MITOCHONDRIAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-31 | — | — | WO | claimed |
| WO-2000011952-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | PRO-NEURON, INC. (US) | 2000-03-09 | — | — | WO | claimed |
| JP-2894610-B2 | — | — | 1999-05-24 | — | — | JP | claimed |
| US-5470838-A | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine | PRO-NEURON, INC. (US) | 1995-11-28 | — | — | US | claimed |
| EP-0339075-B1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1993-08-18 | — | — | EP | claimed |
| EP-0339075-A4 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF. | PRO NEURON INC (US) | 1990-04-10 | — | — | EP | claimed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | claimed |
| WO-1989003837-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | STAT3, JAK2, JAK1 | LMNA 4823/4885THRB 703/4885SMN1; SMN2 3177/4885 |
| US-20010005719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES | POLRMT, TK2, UQCRC1 | LMNA 557/4885THRB 3126/4885SMN1; SMN2 211/4885 |
| US-12528046-B2 | High performance CO2 capture solvent compositions, and CO2 capture systems and processes utilizing same | KAT2A, KLF10, SLC7A1 | LMNA 1741/4885THRB 2743/4885SMN1; SMN2 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.